These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23742732)

  • 1. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy.
    Chavez-Tapia NC; Cesar-Arce A; Barrientos-Gutiérrez T; Villegas-López FA; Méndez-Sanchez N; Uribe M
    Nutr J; 2013 Jun; 12():74. PubMed ID: 23742732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
    Shen YC; Chang YH; Fang CJ; Lin YS
    Nutr J; 2019 Jul; 18(1):34. PubMed ID: 31279342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotics for patients with hepatic encephalopathy.
    McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional support for liver disease.
    Koretz RL; Avenell A; Lipman TO
    Cochrane Database Syst Rev; 2012 May; 2012(5):CD008344. PubMed ID: 22592729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics for people with hepatic encephalopathy.
    Dalal R; McGee RG; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial.
    Riggio O; Ariosto F; Merli M; Caschera M; Zullo A; Balducci G; Ziparo V; Pedretti G; Fiaccadori F; Bottari E
    Dig Dis Sci; 1991 Sep; 36(9):1204-8. PubMed ID: 1893805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of zinc supplementation in the management of chronic liver diseases: A systematic review and meta-analysis.
    Diglio DC; Fernandes SA; Stein J; Azeredo-da-Silva A; de Mattos AA; Tovo CV
    Ann Hepatol; 2020; 19(2):190-196. PubMed ID: 31611064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonabsorbable disaccharides for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc supplementation for the promotion of growth and prevention of infections in infants less than six months of age.
    Lassi ZS; Kurji J; Oliveira CS; Moin A; Bhutta ZA
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD010205. PubMed ID: 32266964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agents for hepatic encephalopathy.
    Junker AE; Als-Nielsen B; Gluud C; Gluud LL
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD003047. PubMed ID: 24515383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic agonists for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003047. PubMed ID: 15495041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D supplementation for chronic liver diseases in adults.
    Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.